Semaglutide vs Tirzepatide Muscle Loss: Which Preserves More Lean Mass?
Updated October 2, 2026
Semaglutide and tirzepatide can produce substantial weight loss, but an important question has emerged alongside the popularity of GLP-1-based obesity medicines:
The question is more complicated than it first appears. Studies of semaglutide and tirzepatide show that both drugs reduce fat mass and also reduce lean mass during weight loss. However, lean mass is not synonymous with skeletal muscle, and results from separate trials cannot be interpreted as a direct head-to-head comparison of muscle preservation.
A 2026 systematic review and meta-analysis of 20 randomized controlled trials involving 15,782 participants estimated that lean mass accounted for approximately 35.2% of weight lost with semaglutide and 25.4% with tirzepatide. However, the authors did not establish that tirzepatide preserves functional skeletal muscle better than semaglutide. The analysis also found that adding resistance training to lifestyle-based weight loss produced a more favorable lean-mass profile than weight loss treatment alone.
So the most accurate interpretation is:
Current evidence suggests that tirzepatide may have a lower proportion of weight loss coming from lean mass than semaglutide, but there is not yet sufficient direct evidence to conclude that tirzepatide definitively preserves more functional skeletal muscle.
This distinction matters because a person can lose lean mass without losing the same amount of contractile muscle tissue, and preservation of strength, physical function and muscle quality may matter more clinically than a DXA-derived lean-mass number alone.
.png)
Semaglutide vs Tirzepatide: What Are We Actually Comparing?
Semaglutide is a GLP-1 receptor agonist, whereas tirzepatide activates both the GIP and GLP-1 receptors.
Both medications reduce appetite and food intake and can produce substantial reductions in body weight. Because body weight is made up of multiple compartments, weight loss generally includes reductions in:
Fat mass Lean soft tissue Body water Glycogen-associated water
For this reason, headlines claiming that a particular GLP-1 drug “causes muscle loss” can be misleading when the underlying study actually measured lean body mass by DXA.
Lean Mass Is Not the Same as Muscle Mass
This is the most important concept in the entire comparison.
DXA and other body-composition techniques divide the body into compartments, but lean mass or fat-free mass is not equivalent to skeletal muscle tissue. Lean compartments can include water and other non-fat tissues in addition to muscle.
A 2024 analysis in the Journal of the Endocrine Society specifically emphasized that changes in fat-free mass should not automatically be interpreted as equivalent changes in skeletal muscle. The authors also noted that some reduction in fat-free mass can accompany substantial reductions in adipose tissue even when the clinical interpretation of the weight loss is favorable.
Therefore:
| Term | What it means | Why it matters |
|---|---|---|
| Lean mass | Non-fat body mass measured by a body-composition method such as DXA | Useful for tracking body composition, but not a direct measure of skeletal muscle alone |
| Fat-free mass | Body mass excluding fat | Includes water and multiple tissues, not only muscle |
| Skeletal muscle mass | Muscle tissue involved in movement and force production | More directly relevant to strength and physical function |
| Muscle strength | Ability to produce force | Provides functional information that body composition alone cannot provide |
| Muscle quality | Relationship between muscle quantity and performance/function | Important because muscle size alone does not fully describe physical capability |
Bottom line: a reported reduction in lean mass should not automatically be translated into the statement “the drug destroyed muscle.”
What Does the Semaglutide Evidence Show?
STEP 1 body-composition analysis
One of the best-known semaglutide body-composition analyses came from an exploratory DXA substudy of the STEP 1 trial.
The substudy included 140 adults with overweight or obesity, of whom 95 received semaglutide 2.4 mg weekly and 45 received placebo. Participants also received lifestyle intervention.
At week 68, the semaglutide group had:
| Measure | Semaglutide result |
|---|---|
| Body weight | −15.0% |
| Total fat mass | −19.3% |
| Regional visceral fat mass | −27.4% |
| Total lean body mass | −9.7% |
| Proportion of body weight represented by lean mass | +3.0 percentage points |
These findings show an important pattern: fat mass fell substantially more than lean body mass. Although absolute lean body mass decreased, the percentage of total body weight represented by lean body mass actually increased.
That is different from saying that semaglutide caused a 9.7% loss of skeletal muscle.
The analysis was exploratory, involved a relatively small DXA subgroup, and was not designed as a direct semaglutide-versus-tirzepatide muscle trial.
View the STEP 1 body-composition analysis
What Does the Tirzepatide Evidence Show?
SURMOUNT-1 DXA substudy
A body-composition substudy of SURMOUNT-1 evaluated 160 participants who had DXA measurements at baseline and week 72.
Pooled tirzepatide treatment produced the following changes:
| Measure | Tirzepatide result |
|---|---|
| Body weight | −21.3% |
| Fat mass | −33.9% |
| Lean mass | −10.9% |
| Approximate composition of weight lost | 75% fat mass / 25% lean mass |
Again, the important point is that most of the weight lost was fat mass.
The study also found broadly similar proportions of fat and lean mass loss across several prespecified subgroups, including different age and sex categories.
However, this was a tirzepatide-versus-placebo DXA substudy, not a semaglutide-versus-tirzepatide randomized body-composition trial.
PubMed: SURMOUNT-1 body-composition study
2026 Meta-Analysis: Semaglutide vs Tirzepatide Lean Mass
The most useful recent comparison comes from a 2026 systematic review and meta-analysis of randomized controlled trials.
The investigators searched PubMed, Embase, Cochrane CENTRAL and Web of Science through January 20, 2026. Twenty randomized controlled trials involving 15,782 participants met the inclusion criteria.
| Intervention | Estimated proportion of total weight lost represented by lean mass | 95% CI |
|---|---|---|
| Semaglutide | 35.2% | 31.5–38.9% |
| Tirzepatide | 25.4% | 22.8–28.0% |
| Liraglutide | 26.8% | 23.1–30.5% |
| Lifestyle intervention | 26.2% | 24.1–28.3% |
| Lifestyle + resistance training | 17.5% | 14.2–20.8% |
These results are important because the pooled estimate was lower for tirzepatide than semaglutide.
But there are several reasons not to turn that finding into an absolute statement that tirzepatide “preserves muscle better.”
Why the numbers do not prove muscle-preservation superiority
First, the analysis pooled different trials. The semaglutide and tirzepatide evidence came from different study populations, treatment durations, protocols and body-composition datasets.
Second, the outcome was lean mass. Lean mass is not equivalent to contractile skeletal muscle.
Third, treatment-related weight loss differed. A drug that produces greater total weight loss can produce a different lean-mass percentage even if the absolute change in lean tissue is similar.
Fourth, study methods matter. DXA, MRI, CT and BIA do not measure exactly the same body-composition variables.
The meta-analysis itself reported moderate heterogeneity, with I² = 68%.
PubMed: 2026 systematic review and meta-analysis
What Does the Direct Semaglutide vs Tirzepatide Trial Show?
The SURMOUNT-5 trial is the most important direct randomized comparison of tirzepatide and semaglutide for obesity without type 2 diabetes.
The phase 3b trial randomized 751 adults to maximum tolerated doses of tirzepatide or semaglutide for 72 weeks.
| Outcome at Week 72 | Tirzepatide | Semaglutide |
|---|---|---|
| Mean percentage body-weight change | −20.2% | −13.7% |
| Mean waist-circumference change | −18.4 cm | −13.0 cm |
Tirzepatide therefore produced greater average weight and waist reduction in this head-to-head trial.
However, SURMOUNT-5 was not primarily designed to determine which treatment preserves skeletal muscle. The principal comparison was body weight, with additional metabolic and clinical outcomes. Therefore, it should not be used as proof that tirzepatide causes less muscle loss than semaglutide.
Does Tirzepatide Preserve More Muscle Than Semaglutide?
The answer depends on what is meant by “preserve more muscle.”
| Question | What the current evidence supports |
|---|---|
| Do both drugs reduce lean mass during weight loss? | Yes. |
| Do both drugs generally reduce substantially more fat than lean mass? | Yes. |
| Does pooled 2026 evidence show a lower proportion of weight loss as lean mass with tirzepatide? | Yes. |
| Does that prove tirzepatide preserves more skeletal muscle? | No. |
| Is there a definitive head-to-head randomized trial using standardized skeletal-muscle and functional outcomes? | Not yet. |
| Can resistance training improve lean-mass preservation during weight loss? | Evidence supports this. |
In other words, tirzepatide currently has a favorable signal on the proportion of weight lost as lean mass, but the clinical question remains incompletely answered.
Why Greater Weight Loss Can Complicate the Muscle-Loss Comparison
One of the easiest mistakes is to compare percentages from different trials without considering how much weight each group lost.
In the STEP 1 DXA substudy, semaglutide was associated with approximately 15% body-weight loss and 9.7% lean-body-mass loss.
In the SURMOUNT-1 DXA substudy, tirzepatide was associated with approximately 21.3% body-weight loss and 10.9% lean-mass loss.
Looking only at these percentages could create the misleading impression that tirzepatide necessarily produces less absolute lean-mass loss simply because a greater fraction of its weight loss was fat.
The two studies were not designed as a head-to-head comparison, so these numbers should primarily be used to understand the pattern of body-composition change rather than to rank the medications.
What About Muscle Strength and Physical Function?
Body composition is only part of the story.
A clinically meaningful assessment of muscle health should ideally include:
Muscle quantity Muscle quality Muscle strength Physical performance Bone health
This is particularly important because a reduction in lean mass does not automatically mean that a person will experience a meaningful decline in strength or function.
Possible functional measurements include:
- Handgrip strength
- Chair-to-stand performance
- Walking speed
- Resistance-training performance
- Other validated physical-function assessments
The American Diabetes Association's obesity-care guidance recommends that clinicians consider regular assessment of muscle strength and function alongside strategies to optimize protein intake and resistance training.
Who May Have Greater Risk of Clinically Important Muscle Loss?
Not everyone losing weight on semaglutide or tirzepatide has the same risk.
Risk may be more important in people who begin treatment with:
- Low muscle mass or suspected sarcopenia
- Advanced age
- Frailty or low physical activity
- Inadequate dietary protein
- Very low calorie intake
- Rapid or prolonged weight loss
- Existing functional limitations
This is one reason body weight alone is an incomplete measure of treatment success.
For a person with obesity and significant excess adiposity, substantial fat loss can be clinically beneficial even when some lean mass is lost. For a leaner or older person with little muscle reserve, however, the same magnitude of lean-mass change may have different implications.
How to Preserve Muscle During Semaglutide or Tirzepatide Treatment
The emerging consensus is that the solution is not simply choosing one incretin drug over another.
A more useful strategy is to address nutrition, resistance exercise and monitoring at the same time.
1. Prioritize adequate protein
Reduced appetite can make it surprisingly difficult to eat enough protein during GLP-1 therapy.
A 2026 joint advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association and The Obesity Society discusses proposed protein targets in the range of approximately 1.2–1.6 g/kg/day during active weight reduction, with individualization based on body size, body composition, health status and treatment goals.
For people with obesity, simply multiplying actual body weight by a protein target may overestimate requirements. Adjusted body weight, ideal body weight or fat-free mass may be more appropriate in some circumstances.
The advisory also notes that adequate protein intake by itself is unlikely to be sufficient to preserve muscle without structured resistance training.
Practical principle: eat protein-rich foods early in the meal, especially when appetite is limited.
2. Perform resistance training
Resistance training is one of the most important modifiable factors for maintaining lean mass during weight loss.
The 2026 joint advisory recommends structured strength training as part of GLP-1-based obesity treatment and discusses a target of regular resistance exercise, customized to the individual's fitness and physical capacity.
A typical program might include:
- Squats or sit-to-stand variations
- Hip-hinge movements
- Rows or pulling exercises
- Pressing exercises
- Step-ups or other lower-body movements
- Progressive resistance as tolerated
Older adults, beginners and people with mobility limitations may require a modified program or professional supervision.
3. Avoid unnecessarily aggressive calorie restriction
Very low calorie intake can make it more difficult to meet protein and micronutrient needs.
Loss of appetite is an expected pharmacologic effect of incretin therapy, but a person who is consistently unable to eat enough food should discuss the issue with their healthcare professional.
4. Monitor body composition when clinically appropriate
Body weight is simple, but it cannot tell you whether weight loss is coming primarily from fat, lean tissue or changes in hydration.
Depending on the clinical setting, monitoring may include:
- DXA: useful for measuring fat mass, lean mass and bone mineral density
- BIA: practical for repeated measurements, although technique and hydration affect results
- CT or MRI: more detailed tissue-level assessment in selected research or clinical settings
- Strength testing: provides functional information not available from body weight alone
- Waist circumference: useful for tracking central adiposity
Consistency is important. Comparing measurements from different devices under different conditions can create apparent changes that are partly methodological.
Semaglutide vs Tirzepatide: Does More Weight Loss Mean More Muscle Loss?
Not necessarily.
The relationship between total weight loss and lean-mass change is complex.
A person losing more total body weight may lose more absolute lean tissue simply because the overall magnitude of weight loss is larger, while still having a favorable fat-to-lean loss ratio.
That is why the clinically meaningful target is not “zero lean-mass loss” at all costs.
Wegovy vs Zepbound: What Should Patients Know?
Wegovy contains semaglutide, while Zepbound contains tirzepatide.
Searches for “Wegovy vs Zepbound muscle loss” and “semaglutide vs tirzepatide muscle loss” are essentially asking the same underlying body-composition question.
The current evidence suggests:
| Issue | What the evidence indicates |
|---|---|
| Average weight loss | Tirzepatide produced greater weight loss than semaglutide in SURMOUNT-5 |
| Fat loss | Both substantially reduce fat mass |
| Lean mass | Both reduce lean mass during substantial weight loss |
| Proportion of weight lost as lean mass | Lower pooled estimate with tirzepatide in the 2026 meta-analysis |
| Proof of superior skeletal-muscle preservation | Not established |
| Resistance training | Important for lean-mass preservation regardless of drug |
| Protein adequacy | Important, particularly when appetite is suppressed |
What About New Muscle-Sparing Obesity Drugs?
The obesity-drug field is increasingly moving beyond the question of how much weight can be lost toward the question of what type of tissue is lost during treatment.
This has led to research into combination treatments designed to increase fat loss while limiting reductions in lean tissue.
One example is trevogrumab, an investigational therapy targeting the myostatin pathway. In September 2026, Regeneron reported results from the COURAGE program evaluating trevogrumab in combination with semaglutide, with the company reporting substantially greater lean-mass preservation than semaglutide alone.
These findings are important scientifically but should not be interpreted as establishing an approved muscle-preserving treatment. Trevogrumab remains investigational, and longer-term evidence concerning muscle strength, function, safety and clinical outcomes is still needed.
The emerging research suggests that the future of obesity treatment may increasingly focus on fat-selective weight loss and preservation of muscle and physical function, rather than the scale number alone.
How Strong Is the Evidence?
| Evidence question | Evidence level | Interpretation |
|---|---|---|
| Semaglutide produces substantial weight and fat loss | E4 | Supported by large randomized clinical trials |
| Tirzepatide produces substantial weight and fat loss | E4 | Supported by large randomized clinical trials |
| Both treatments reduce lean mass during substantial weight loss | E3–E4 | Supported by body-composition substudy data and evidence syntheses |
| Tirzepatide has a lower pooled proportion of weight loss represented by lean mass | E3 | Supported by the 2026 meta-analysis, but based on cross-trial comparisons |
| Tirzepatide definitively preserves skeletal muscle better than semaglutide | E2 | Direct comparative evidence remains insufficient |
| Resistance training helps preserve lean mass during weight loss | E4 | Supported by broader weight-loss and exercise evidence |
| Adequate protein supports muscle preservation | E3–E4 | Supported by clinical nutrition evidence and expert consensus |
Evidence grading note: Evidence levels reflect the strength and directness of evidence for the specific question, not the overall effectiveness of either medication.
Frequently Asked Questions
Does tirzepatide cause less muscle loss than semaglutide?
A 2026 meta-analysis found that lean mass represented approximately 25.4% of weight lost with tirzepatide compared with 35.2% with semaglutide. However, this was a cross-trial pooled analysis rather than a randomized head-to-head body-composition trial, so it does not prove superior preservation of functional skeletal muscle.
Does semaglutide cause muscle loss?
Semaglutide treatment is associated with reductions in lean body mass during substantial weight loss. In the STEP 1 DXA substudy, total lean body mass decreased by 9.7%, while fat mass decreased by 19.3%. The lean-mass finding should not be interpreted as an equivalent percentage loss of skeletal muscle.
Does tirzepatide cause muscle loss?
Tirzepatide is also associated with reductions in lean mass during weight loss. In the SURMOUNT-1 DXA substudy, lean mass declined by 10.9%, while fat mass declined by 33.9%. Approximately 75% of body weight lost was fat mass and 25% lean mass.
Which GLP-1 is best for preserving muscle?
Current evidence does not establish a definitive winner for functional skeletal-muscle preservation. The available data suggest a lower proportion of weight loss as lean mass with tirzepatide, but direct comparative measurements of skeletal muscle quantity, quality and physical function remain limited.
Can you build muscle while taking semaglutide or tirzepatide?
Muscle gain may be possible, particularly when resistance training and adequate nutrition are maintained, but the degree of muscle gain depends on factors including training status, protein intake, energy balance, age and overall health. During active weight loss, the immediate goal for many people is often preservation rather than rapid muscle gain.
How much protein should I eat on a GLP-1?
Several 2025–2026 expert recommendations discuss approximately 1.2–1.6 g/kg/day during active weight reduction, but the appropriate calculation method varies, particularly in people with obesity, kidney disease or other medical conditions. A clinician or dietitian can individualize the target.
Does resistance training help prevent GLP-1 muscle loss?
Yes. Resistance training is one of the principal evidence-supported strategies for preserving lean mass and physical function during weight reduction and is recommended as part of a comprehensive approach to GLP-1-based obesity treatment.
Is lean mass loss always harmful?
No. Lean-mass measurements include more than skeletal muscle, and substantial weight loss can change multiple body compartments. The clinical significance depends on muscle strength, physical function, baseline muscle reserve, age, nutritional status and other factors.
The Bottom Line
Semaglutide and tirzepatide both produce substantial fat loss and both can reduce lean mass during weight reduction.
The strongest current comparative signal comes from a 2026 meta-analysis in which approximately 35.2% of weight lost with semaglutide and 25.4% with tirzepatide was estimated to consist of lean mass.
That finding is important, but it should not be turned into a simplistic statement that “tirzepatide does not cause muscle loss” or that it has conclusively been proven to preserve skeletal muscle better than semaglutide.
The evidence supports a more precise conclusion:
Both drugs can reduce lean mass during major weight loss. Tirzepatide shows a lower pooled proportion of weight loss as lean mass than semaglutide, but whether that translates into superior preservation of actual skeletal muscle, strength and physical function remains uncertain.
For people using either medication, the modifiable factors may ultimately matter more than focusing exclusively on the drug comparison: adequate protein intake, progressive resistance training, avoiding unnecessary nutritional restriction and monitoring body composition and physical function when appropriate.
References & Primary Sources
1. Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes Obesity and Metabolism. 2026;28(6):4818–4827. DOI: 10.1111/dom.70666. PubMed
2. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025;393:26–36. DOI: 10.1056/NEJMoa2416394. PubMed
3. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. 2025;27(5):2720–2729. DOI: 10.1111/dom.16275. PubMed
4. Wilding JPH, Batterham RL, Calanna S, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Journal of the Endocrine Society. 2021;5(Suppl 1):A16–A17. DOI: 10.1210/jendso/bvab048.030. Full article
5. Tinsley GM, Heymsfield SB. Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments. Journal of the Endocrine Society. 2024;8(11):bvae164. DOI: 10.1210/jendso/bvae164. Full article
6. Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. PMC full text
Medical Disclaimer
This article is for educational purposes and does not provide individualized medical advice. Do not change, stop or combine prescription medicines based solely on information in this article. Protein targets, exercise programs and body-composition monitoring should be individualized, particularly for people who are older, frail, undernourished or living with kidney disease or other chronic conditions.
Comments